Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones


- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolR?-expressing cancers -

View original post here:
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Related Posts